Research programme: schizophrenia therapeutic - QLT USA

Drug Profile

Research programme: schizophrenia therapeutic - QLT USA

Alternative Names: Atrigel® risperidone; Risperidone implant - QLT USA; Sustained release risperidone - QLT USA

Latest Information Update: 11 Nov 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator QLT USA
  • Class Pyrimidinones
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 22 Nov 2004 Atrix Laboratories has been acquired by QLT
  • 11 Aug 2004 Preclinical trials in Schizophrenia in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top